Detalles de la búsqueda
1.
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
Int J Cancer
; 154(5): 863-872, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37840339
2.
[Further Development and Interoperability in Oncological Care Structures, Quality Control and Research]. / Weiterentwicklung und Vernetzung der onkologischen Versorgungsstrukturen, der Qualitätssicherung und der Forschung.
Gesundheitswesen
; 85(7): 649-656, 2023 Jul.
Artículo
en Alemán
| MEDLINE | ID: mdl-36328158
3.
Integrated, cross-sectoral psycho-oncology (isPO): a new form of care for newly diagnosed cancer patients in Germany.
BMC Health Serv Res
; 22(1): 543, 2022 Apr 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35459202
4.
Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.
Int J Cancer
; 149(6): 1322-1331, 2021 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019698
5.
[Hospital inhouse contact tracing-significant impact to patient care during the coronavirus pandemic]. / Krankenhausinterne Kontaktpersonennachverfolgung Ein wichtiger Beitrag zur Sicherstellung der Patientenversorgung in der SARS-CoV-2-Pandemie.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
; 64(6): 755-762, 2021 Jun.
Artículo
en Alemán
| MEDLINE | ID: mdl-34021363
6.
Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial.
Int J Cancer
; 145(8): 2282-2291, 2019 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30868576
7.
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
BMC Cancer
; 19(1): 504, 2019 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31138244
8.
Suspected seizure-survival of a lethal dose of the rodenticide alpha-chloralose.
Anaesthesist
; 68(12): 843-847, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31701172
9.
Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer.
Int J Cancer
; 140(9): 2134-2144, 2017 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28124380
10.
Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society.
BMC Cancer
; 17(1): 850, 2017 Dec 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29241445
11.
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
Eur J Haematol
; 99(1): 42-50, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28370401
12.
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
BMC Cancer
; 16: 290, 2016 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27114074
13.
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Lancet Oncol
; 16(13): 1355-69, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26361971
14.
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 16(8): 979-89, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26189067
15.
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).
Clin Cancer Res
; 30(7): 1256-1263, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38289994
16.
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
Leukemia
; 38(3): 640-647, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38062124
17.
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
J Clin Oncol
; 42(1): 26-37, 2024 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37753960
18.
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
Leukemia
; 38(6): 1307-1314, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38678093
19.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Lancet Haematol
; 11(2): e101-e113, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38302221
20.
Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma.
Blood
; 118(24): 6292-8, 2011 Dec 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-21917759